LRMR · Larimar Therapeutics, Inc.
$4.19
+0.03 (+0.60%)
At close · Aug 21
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“these cash resources are not sufficient to fund the Company's planned operations for a period of at least one year from the date these unaudited condensed consolidated financial statements are issued. ... There is no assurance, however, that additional financing will be available when needed or that the Company will be able to obtain financing on terms acceptable to the Company. ... These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$441.50M
Shares
103.88M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.16
Open$4.21
Day$3.98–4.21
52W close$2.81–5.95
Avg vol 30d1.4M
Short int12.2M · 11.7% float · 9.4d
Short vol43%
Last earningsMay 15, 2023
DataJan 2020–Aug 2026
Filing10-Q · Aug 4
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+9%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+4%
trailing
6-month return
−22%
trailing
YTD return
+9%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +32 funds added
Insider flow
Accumulating
Net +$166.9K over 90 days · 0% sells
Short interest
Rising
11.73% of float · ▲ +7.8% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
EPS growth
−57%
Y/Y
Free cash flow
$-113.3M
Balance sheet
$70.9M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +32 funds added
Insider flow
Accumulating
Net +$166.9K over 90 days · 0% sells
Short interest
Rising
11.73% of float · ▲ +7.8% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $4 · 43%
Range high $6
vs 200-day avg +7%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash, cash equivalents and marketable securities | $156.3M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LRMR
this stock
Larimar Therapeutics, Inc.
|
$441.50M | +9.2% | — | — | 11.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LRMR | -2.6% | +3.7% | -21.7% | +8.9% | +9.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -0.6% | +0.4% | -32.8% | +6.8% | -2.6% |